DARE Dare Bioscience Inc.

0.75
+0.03  (+5%)
Previous Close 0.72
Open 0.7
Price To Book 0.89
Market Cap 8560910
Shares 11,422,161
Volume 64,013
Short Ratio
Av. Daily Volume 321,466

SEC filingsSee all SEC filings

  1. 8-K - Current report 181226303
  2. 8-K - Current report 181220688
  3. 8-K - Current report 181208515
  4. 8-K - Current report 181203134
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181175221

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b trial to be initiated in 2019 with data due 4Q 2020.
Sildenafil Cream, 3.6%
Female Sexual Arousal Disorder (FSAD)
Phase 2 top-line data due 2H 2019.
Ovaprene
Contraception
Phase 3 trial to be initiated 2H 2019.
DARE-BV1
Bacterial Vaginosis
Phase 1 top-line data due 2H 2019.
DARE-HRT1
Hormone replacement therapy

Latest News

  1. Edited Transcript of DARE earnings conference call or presentation 13-Nov-18 1:30pm GMT
  2. New Healthcare Trends Pushing Stocks Higher On Thursday
  3. Daré Bioscience, Inc. Announces Licensing and Global Rights to Novel Phase III Product Candidate for the Treatment of Bacterial Vaginosis
  4. DARE: Ovaprene PCT Continues. TS Content Validity Study, Thermographic Study Underway
  5. Daré Bioscience, Inc. Announces Initiation of Content Validity Study for Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
  6. Daré Bioscience, Inc. Announces Enrollment in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
  7. Daré Bioscience Provides Business Update and Announces Third Quarter Financial Results
  8. Daré to Host Third Quarter 2018 Financial Results Conference Call and Webcast
  9. Daré Announces Two Late-Breaking Abstracts to be Presented at the American Association of Pharmaceutical Scientists (AAPS) in Washington D.C.
  10. Daré Bioscience, Inc. to Present at the Dawson James Small Cap Growth Conference
  11. Daré Bioscience, Inc. to Present at the 2018 BIO Investor Forum
  12. DARE: Upcoming Milestones Inc FDA Feedback on Topical Sildenafil FSAD Program
  13. Greg Matz Joins Daré Bioscience Board of Directors
  14. Daré Bioscience, Growing Through Collaborations, Male Contraceptive, Analysts Target
  15. Free Daily Technical Summary Reports on Dermira and Three Other Biotech Stocks

SEC Filings

  1. 8-K - Current report 181226303
  2. 8-K - Current report 181220688
  3. 8-K - Current report 181208515
  4. 8-K - Current report 181203134
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181175221
  6. 8-K - Current report 181175113
  7. 424B5 - Prospectus [Rule 424(b)(5)] 181087989
  8. 424B3 - Prospectus [Rule 424(b)(3)] 181086146
  9. EFFECT - Notice of Effectiveness 181082556
  10. EFFECT - Notice of Effectiveness 181082553